Impact of Personalized Rehabilitation Guidance

December 23, 2024 updated by: Yan Dong

Impact of Personalized Rehabilitation Guidance Based on WeChat Official Accounts Platform on Functional Recovery and Quality of Life of Patients with Knee Osteoarthritis

To investigate the impact of personalized rehabilitation guidance based on the WeChat Official Accounts Platform on the functional recovery and quality of life of patients with knee osteoarthritis (KOA).Ninety patients diagnosed with KOA undergoing joint replacement were included via convenient sampling.The patients were randomly divided into an observation group and a control group,with 45 patients in each group.The control group received traditional rehabilitation guidance,while the observation group received personalized rehabilitation guidance through the WeChat Official Accounts Platform in addition to the traditional guidance.Different care plans had varying effects on patients' scores on the 36-item Short Form Health Survey (SF-36),Visual Analog Scale (VAS),and Lysholm Knee Scoring Scale.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
90

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Anhui
      • Fuyang City, Anhui, China, 236000
        • Fuyang Hospital Of Anhui Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • aged 50 to 80 years;
  • conscious, without cognitive impairments, and able to complete reading independently or with assistance;
  • able to operate a smartphone and use WeChat;
  • willing to participate in this study and provide signed informed consent.

Exclusion Criteria:

  • acute cerebrovascular disease with sequelae in the past 6 months;
  • coexisting primary psychiatric disorders;
  • unable to perform physical exercise due to physical disability in the lower limbs;
  • postoperative complications, such as deep vein thrombosis or infection;
  • participation in other interventional studies.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: control group
Behavioral: conventional nursing care
(1) Preoperative education: An appropriate walking aid was provided for the patient and instructions were given to guide correct use, while isometric muscle exercises were taught. (2) Postoperative care: Six hours after anesthesia recovery, the head of the patient's bed could be elevated as needed, and the patient was instructed to perform ankle pumps (dorsiflexion and plantarflexion of the ankle).(3) Postoperative exercise: One to two days after surgery, following the removal of the drainage tube, the patient was encouraged to continue with ankle pumps and isometric quadriceps contractions, as well as to begin straight-leg raises. (4) Postoperative Day 3: In strict accordance with medical advice and under the guidance of a physiotherapist, patients engaged in continuous passive motion therapy for the affected knee, along with manual knee joint massage. (5) Postoperative Days 5-7: the patient would try to stand with the assistance of a walker, gradually progressing to walking exercises
Experimental: observation group
Behavioral: Intervention Care
(1) Intervention Day 1: (i) All patients in the observation group were provided with an introduction to the study and invited to join the WeChat group for the observation group. (2) Intervention Day 2: Exercise guidance for patients with KOA was shared via the WeChat group.(3) Intervention Day 3: Guidance for emotional regulation was sent to the patients with KOA via the WeChat group.(4) Intervention Week 1: A micro-lesson on KOA-related knowledge was delivered via the WeChat group to deepen patients' understanding. (5) Intervention Week 2: (i) Text instructions and related questions on common conservative treatments for KOA, including topical and oral painkillers, were shared, with correct answers provided the next day.(ii) A micro-lesson on exercise guidance for patients with KOA was uploaded to the WeChat group to reinforce patients' understanding.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
The 36-item Short Form Health Survey (SF-36)
Time Frame: at 1 week and 1 month post-discharge
The SF-36 is a concise health survey divided into 8 subscales: physical function, role physical, bodily pain, global health, vitality, social function, role emotional, and mental health, where a higher score indicates a better health status.
at 1 week and 1 month post-discharge
Visual Analog Scale (VAS)
Time Frame: at 1 week and 1 month post-discharge
The VAS was used to assess pain levels before and after treatment in the two groups. VAS scores are positively correlated with pain intensity, where 0 indicates no pain and 10 indicates the most severe pain. A score of ≤3 is defined as mild pain, 4-6 as moderate pain, and ≥7 as severe pain.
at 1 week and 1 month post-discharge
Lysholm Knee Scoring Scale
Time Frame: at 1 week and 1 month post-discharge
The Lysholm Knee Scoring Scale was employed to evaluate knee function. This scale covers eight aspects, including limping, support, restraining, instability, pain, swelling, climbing stairs, and squatting. It is scored on a scale of 0 to 100. The total score is 100 points, with higher scores indicating fewer symptoms and higher levels of functioning. A score above 95 is considered excellent, 85-94 is good, 65-84 is fair, and less than 65 is poor.
at 1 week and 1 month post-discharge
The Newcastle Satisfaction with Nursing Scale (NSNS)
Time Frame: at 1 week and 1 month post-discharge
The Newcastle Satisfaction with Nursing Scale (NSNS) was used to measure patient satisfaction with nursing care. This scale consists of 19 items, such as nurse competence, communication, emotional support, and safety management. Each item is rated on a scale of 1-5, with a total score ranging from 19 to 95 points. A score of ≥77 indicates very satisfied, 58-76 indicates satisfied, 39-57 indicates moderately satisfied, and ≤38 indicates dissatisfied.
at 1 week and 1 month post-discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Yan Dong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 15, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 1, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 18, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 23, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 25, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 23, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Fuyang Affiliated Hospital 001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Knee Osteoarthritis

Clinical Trials on conventional nursing care

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings